Emily Edson‐Heredia
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Hair Growth and Disorders, Health Systems, Economic Evaluations, Quality of Life, Fibromyalgia and Chronic Fatigue Syndrome Research
Most-Cited Works
- → Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis(2012)929 cited
- → Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study(2021)111 cited
- → Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis(2014)107 cited
- → Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )(2020)106 cited
- → Development of a Disease-Specific Version of the EQ-5D-5L for Use in Patients Suffering from Psoriasis: Lessons Learned from a Feasibility Study in the UK(2013)100 cited
- → Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink(2014)94 cited
- → Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis(2016)92 cited
- → Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis(2013)83 cited
- → Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study(2019)76 cited
- → The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis(2014)69 cited